INC (NASDAQ:INCR) Files An 8-K Completion of Acquisition or Disposition of AssetsItem 2.01 Completion of Acquisition or Disposition of Assets.
On December 30, 2017, Cleveland Gary, CEO of Healthway Shopping Network, Inc entered into an agreement with James Kimble of Arcade Travel, Inc. to purchase 49% ownership of Arcade Travel.
There is no prior relationship between Cleveland Gary, directors, affiliates, officers, or any associate of any officer or director of Healthway Shopping Network other than in respect to this transaction.
Under the terms and subject to the conditions of the Purchase Agreement, Cleveland Gary, CEO Healthway Shopping Network agreed to pay James Kimble, Arcade Travel 8,000,000 common shares of Healthway Shopping Network Inc. stock for the acquisiiton of 49% of Arcade Travel.
The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on June 13, 2017 and is incorporated herein by reference.
(d) Exhibits.
2.1 Purchase Agreement
See Exhibit Index.
About INC (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
